Format

Send to

Choose Destination
Clin Rheumatol. 2007 Jun;26(6):984-7. Epub 2006 Apr 22.

Infliximab in Takayasu arteritis: a safe alternative?

Author information

1
Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece.

Abstract

OBJECTIVE:

To test the efficacy of Infliximab, a chimeric monoclonal antibody against TNF-alpha, in the treatment of Takayasu arteritis.

MATERIALS AND METHODS:

We used infliximab at an initial dose of 3 mg/kg i.v. at weeks 0, 2, 6, and 8 thereafter in combination with methotrexate or azathioprine, to treat four patients with Takayasu arteritis.

RESULTS:

Three out of four patients responded to infliximab treatment, while two of them retained the response during a two-year follow up. A higher dose regimen (5 mg/kg), however, was eventually warranted for two of the responders. No major side effects were noted.

CONCLUSIONS:

Infliximab might be an effective and safe alternative for patients with Takayasu arteritis.

PMID:
16633710
DOI:
10.1007/s10067-006-0227-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center